We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (SATELITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04871191
Recruitment Status : Not yet recruiting
First Posted : May 4, 2021
Last Update Posted : June 8, 2022
Sponsor:
Collaborator:
URC-CIC Paris Descartes Necker Cochin
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy. It will evaluate the efficacy to induce remission of three different salvage strategies including: a combination of rituximab with addition of a conventional disease-modifying antirheumatic drugs (either methotrexate, azathioprine or mycophenolate mofetil, but preferentially methotrexate); tocilizumab; or abatacept.

Condition or disease Intervention/treatment Phase
Granulomatosis With Polyangiitis Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Drug: Rituximab Drug: Tocilizumab Drug: Abatacept Phase 2

Detailed Description:

Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV).

Combination of glucocorticoids and either cyclophosphamide or rituximab is the standard of care for remission-induction of new-onset organ-threatening or life-threatening GPA. Few patients fail to respond to both cyclophosphamide and rituximab, but it is not uncommon for patients to have persistent disease activity resulting in inability to taper glucocorticoids, which is also considered refractory disease. The current recommendations for patients with GPA refractory to remission-induction therapy are to switch from cyclophosphamide to rituximab or from rituximab to cyclophosphamide. However, there are no recommendations for the management of patients with inadequate response after both treatments. Treatment with a biologic disease-modifying antirheumatic drugs (DMARD) or a combination of rituximab and a cDMARD are potential treatments options but have not been properly evaluated in such cases. Among biologic DMARD that have been evaluated in AAV, some have shown promising results, including tocilizumab and abatacept.

Identifying the most promising therapeutic strategy for patients with GPA and inadequate response to standard of care therapy may improve management of GPA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis
Estimated Study Start Date : September 2022
Estimated Primary Completion Date : February 2026
Estimated Study Completion Date : June 2026


Arm Intervention/treatment
Active Comparator: Rituximab + cDMARD
Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
Drug: Rituximab
375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
Other Name: Mabthera

Experimental: Tocilizumab
Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
Drug: Tocilizumab
Subcutaneous injection of 162 mg per week
Other Name: RoActemra

Experimental: Abatacept
Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
Drug: Abatacept
Subcutaneous injection of 125 mg per week
Other Name: Orencia




Primary Outcome Measures :
  1. Proportion of patients with a response or a remission [ Time Frame: week 12 ]
    defined according to the EULAR recommendations. Remission is defined as the absence of disease activity attributable to active disease qualified by the need for ongoing stable maintenance immunosuppressive therapy. The term ''active disease'' is not restricted to vasculitis only, but also includes other inflammatory features like granulomatous inflammation. Response is defined as a 50% reduction of disease activity score and absence of new manifestations.


Secondary Outcome Measures :
  1. Proportion of patients with a response or a remission at week 26 and 52. [ Time Frame: week 26 and 52 ]
    according to the EULAR recommendations

  2. Physician's and patient's global assessment of disease activity [ Time Frame: week 12 and 52 ]
    The difference between the physician's and patient's global assessment of disease activity between baseline and week 12 and between baseline and week 52 using a scale ranging from 0 to 100, with higher scores indicating more activity.

  3. Patient-reported outcomes [ Time Frame: week 12, 24 and 52 ]
    The patient-reported outcomes (PRO) including the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire, a 29-item profile measure comprising six domains, with higher scores meaning more active disease, at week 12, 24, and 52 after randomization, and during the long-term follow-up.

  4. Adverse events [ Time Frame: week 26 and 52 ]
    The number of adverse events, expressed as adverse events according to the CTCAE toxicity grading system per patient-year at week 26 and 52 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions

  5. Corticosteroids use [ Time Frame: week 26 and 52 ]
    The area under the curve for corticosteroids at week 26 and 52

  6. Vasculitis Damage Index [ Time Frame: week 26 and 52 ]
    The Vasculitis Damage Index (VDI, scoring from 0 to 58, higher scores indicating more damage) at week 26 and 52

  7. Health Assessment Questionnaire (HAQ) [ Time Frame: week 26 and 52 ]
    ranging from 0 to 3, with higher scores indicating worse functional impairment

  8. Short Form 36 (SF-36) Health questionnaire [ Time Frame: week 26 and 52 ]
    scores range from 0 to 100 for each component, with lower scores indicating greater impairment of quality of life

  9. ANCA titers [ Time Frame: week 26 and 52 ]
    Evolution of ANCA titers in the treatment groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed or relapsing granulomatosis with polyangiitis according to American College of Rheumatology criteria, EMA classification algorithm and/or the 2012 revised Chapel Hill Consensus Conference definition.
  • Aged 18 years or older
  • Active clinical manifestations attributable to GPA
  • An inadequate response to previous standard of care therapy including

    1. Both a combination of glucocorticoids plus cyclophosphamide and a combination of glucocorticoids plus rituximab
    2. Or an inadequate response to a combination of glucocorticoids plus rituximab and a contraindication to cyclophosphamide
  • An inadequate response to treatment defined as follows:

    1. A progressive disease unresponsive to previous standard of care therapy after 12 weeks of treatment
    2. Or a lack of response, defined as < 50% reduction in the disease activity score, after 12 weeks of treatment
    3. Or a persistent active disease attributable to either a vasculitic or a granulomatous manifestation of GPA that requires the maintenance of corticosteroids ≥ 7.5 mg/day of equivalent prednisone after ≥ 12 weeks of treatment.
  • A stable dose of oral glucocorticoids of ≥ 7.5 mg/day of equivalent prednisone within the 4 weeks before enrollment. Pulses of methylprednisolone (1 to 3 pulses of 7.5 to 15 mg/kg each; ≤ 1000 mg) are allowed if necessary, according to severity before starting the experimental treatment.
  • A stable dose of conventional disease-modifying anti-rheumatic drugs (cDMARD) within 4 weeks before enrollment if the patient is currently treated with a cDMARD
  • Patients must have the ability to understand the requirements of the study, provide written informed consent prior to participation in the study (including consent for the use and disclosure of research-related health information) and comply with the study protocol procedures (including required study visits)
  • Patients must have an affiliation with a mode of social security (profit or being entitled)

Exclusion Criteria:

  • An allergy or hypersensitivity to monoclonal antibodies or either of the study drugs (rituximab, abatacept or tocilizumab) or to their excipients
  • A previous treatment with a combination of rituximab plus a cDMARD, with abatacept, or with tocilizumab
  • A contraindication to a combination of rituximab plus a cDMARD, to abatacept, or to tocilizumab (including an ongoing infection; history of recent cancer <5 years before enrollment, except for cured non-melanoma skin cancer); pregnancy; and breastfeeding.
  • Patients with severe vasculitis manifestations that requires plasma exchange therapy including severe renal failure with a creatinine level ≥350 µmol/L or severe alveolar haemorrhage
  • Patients with vasculitis in remission
  • Patients with symptoms attributable to chronic and non-active GPA
  • Patients with severe cardiac failure defined as class IV in New York Heart Association
  • Patients with acute infections or chronic active infections (including HIV, HBV or HCV)
  • Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment
  • Pregnant women and lactation. All women with childbearing potential are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception from the date of consent through the end of the study, and for women who are taking abatacept through 14 weeks after the last treatment administration, for women who are taking tocilizumab through 3 months after the last treatment administration, for women who are taking rituximab in combination with methotrexate through 6 months after the last treatment administration, for women who are taking rituximab in combination with mycofenolate mofetil or with azathioprine through 3 months after the last treatment administration
  • Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol
  • Patients included in other investigational therapeutic study within the previous 3 months
  • Patients suspected not to be observant to the proposed treatments
  • Laboratory parameter exclusions

    1. aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) > 5 times upper limit of normal
    2. Platelet count <100.000/mm3
    3. White blood cell count <2000/mm3

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04871191


Contacts
Layout table for location contacts
Contact: Jonathan London, MD +33 1 44 64 16 02 jlondon@hopital-dcss.org
Contact: Audrey Beclin-Clabaux +331 58 41 33 82 audrey.clabaux@aphp.fr

Locations
Layout table for location information
France
Hôpital de la Croix Saint Simon
Paris, France, 75020
Contact: Jonathan London, MD    + 33 1 44 64 16 02    jlondon@hopital-dcss.org   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Investigators
Layout table for investigator information
Study Director: Benjamin Terrier, MD, PhD AP-HP - Service médecine interne
Publications:

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04871191    
Other Study ID Numbers: P200026
First Posted: May 4, 2021    Key Record Dates
Last Update Posted: June 8, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Granulomatosis with Polyangiitis
Anti-neutrophil cytoplasmic antibody
Salvage therapy
Standard of care therapy
Inadequate response
Additional relevant MeSH terms:
Layout table for MeSH terms
Granulomatosis with Polyangiitis
Vasculitis
Systemic Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Autoimmune Diseases
Immune System Diseases
Rituximab
Abatacept
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents